Investigation of the therapeutic efficacy and resistance mechanisms of lytic phages targeting ST218 KL57 CR-hvKP

Lei Dou, Jiayang Li, Wenqi Wu, Li Xu, Mingjie Qiu, Shuanghong Yang, Jiajie Wang, Sai Tian, Zhitao Zhou, Meilin Wu, Yun Zhao, Xiuwen Wu, Jianan RenmSystems 2026 · DOI

TL;DR

This study investigates the therapeutic potential of two novel bacteriophages (JLBP1001 and JLBP1002) against carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP) in a mouse model. The research reveals that phage resistance in in vivo settings primarily arises from mutations within the capsular polysaccharide (CPS) gene cluster, offering crucial insights for optimizing phage therapy against these challenging infections.

What Problem Does This Paper Address?

The escalating global crisis of antibiotic resistance has spurred renewed interest in bacteriophage therapy as a promising alternative. However, the widespread clinical application of phages is hampered by the emergence of phage-resistant bacterial strains. Understanding the mechanisms behind this resistance, particularly how it differs between laboratory (in vitro) and real-world (in vivo) environments, is critical for developing effective and sustainable phage-based treatments. This paper specifically addresses this gap by investigating the therapeutic efficacy of two lytic phages against a clinically relevant CR-hvKP strain and dissecting the mechanisms of resistance that develop within a living host.

Methods

The researchers employed a multi-pronged approach:

  • Phage Isolation and Characterization: Two lytic phages, JLBP1001 and JLBP1002, were isolated from sewage and characterized for their plaque morphology, transmission electron microscopy (TEM) features, optimal multiplicity of infection (MOI), and stability across different pH and temperature conditions.
  • In Vivo Efficacy Study: A mouse intra-abdominal infection (IAI) model was used to assess the therapeutic efficacy of the phages, both as monotherapies and in combination with meropenem (a common antibiotic). Survival rates and bacterial burden in various organs were measured.
  • Phage Resistance Isolation and Analysis: Phage-resistant K. pneumoniae mutants (RM strains) were isolated from surviving mice. These mutants were then subjected to:
  • Whole-Genome Sequencing (WGS): To identify genetic mutations responsible for resistance.
  • Transcriptomic Analysis: To understand changes in gene expression related to resistance mechanisms.
  • Metabolomic Analysis: To investigate alterations in metabolic pathways.
  • Phenotypic Assays: Including capsule production, mucoviscosity, biofilm formation, and phage adsorption efficiency, to correlate genetic changes with observable traits.
  • Functional Studies: Genetic engineering techniques (knockout, complementation, and point mutation) were used to explore the specific role of the putA gene in phage resistance.

Datasets

The study utilized a clinical isolate of Klebsiella pneumoniae (JLKP186) and 48 other K. pneumoniae strains for host range determination. The genomic sequences of the isolated phages (JLBP1001 and JLBP1002) were submitted to GenBank (accession numbers PP973870.1 and PP994489.1). RNA-seq data from the study were deposited in the NCBI database (PRJNA1256399), and metabolomics data were uploaded to MetaboLights (MTBLS12480).

Key Insights and Ideas

  • In Vivo Resistance Mechanisms Differ: The study highlights that resistance mechanisms observed in vivo can differ from those seen in vitro. While both phages showed therapeutic promise, the resistance that emerged in the mouse model provided unique insights.
  • CPS Gene Cluster is a Hotspot for Resistance: A significant finding is that the majority of phage-resistant mutants isolated from mice had mutations within the capsular polysaccharide (CPS) gene cluster. This suggests that altering the bacterial surface, which phages often use as an entry point, is a primary strategy for evading phage infection.
  • Beyond Direct Mutations: Interestingly, some resistant strains (RM01, RM02, RM12) developed resistance not through direct mutations in the CPS genes themselves, but by downregulating CPS production and related transcriptional regulators. This points to a more complex regulatory network involved in resistance.
  • The Role of putA: The study identified mutations in the putA gene in several resistant strains. While putA deletion alone didn't confer resistance, a specific point mutation in putA in the JLKP186 background led to reduced phage sensitivity, suggesting a role for proline metabolism in phage-bacteria interactions.
  • Phage-Antibiotic Synergy: The combination of phage JLBP1001 and meropenem showed a strong synergistic effect, indicating that combining phage therapy with antibiotics could be a powerful strategy to overcome resistance and enhance treatment outcomes.

Key Results

  • Therapeutic Efficacy: Both JLBP1001 and JLBP1002 significantly improved mouse survival and reduced bacterial burden in an IAI model of CR-hvKP infection. JLBP1001 demonstrated a 100% survival rate at optimal MOIs.
  • Phage Resistance Mechanisms:
    • 16 out of 21 isolated resistant strains (76.19%) had mutations in the CPS gene cluster, affecting genes like wbap, wzc, and wzy.
  • Strains RM01, RM02, and RM12 showed resistance without direct CPS gene mutations, linked to downregulation of CPS and regulators.
  • A putA point mutation (1894T>C) in JLKP186 led to reduced phage sensitivity.
  • Fitness Trade-offs: Most resistant strains exhibited reduced virulence, decreased mucoviscosity, and lower CPS production, suggesting a fitness cost associated with resistance. However, some strains (RM03, RM21) maintained virulence, indicating complex adaptive strategies.
  • Phage-Antibiotic Synergy: Phage JLBP1001 showed a synergistic effect with meropenem, with a calculated FICI < 0.5.

Limitations and Future Work

The authors acknowledge several limitations:

  • Functional Validation: While WGS and transcriptomic analyses identified candidate resistance mechanisms, not all putative determinants were functionally validated. Further genetic and biochemical confirmation is needed.
  • Host Immune Environment: The influence of the complex host immune environment on resistance evolution remains unclear and warrants further investigation.
  • Uncharacterized Mutated Regions: Several frequently mutated regions in resistant isolates remain uncharacterized, requiring future work to elucidate their regulatory roles and contributions to phage adaptation.

The study suggests that future work should focus on:

  • Dissecting the precise mechanisms by which putA mutations influence phage infection.
  • Investigating the interplay between the host immune system and phage resistance development.
  • Exploring the potential of combining phage therapy with antibiotics to mitigate resistance and hypervirulence.
  • Further characterizing the regulatory roles of uncharacterized mutated regions in phage adaptation.

Summary updated

Abstract

Carbapenem-resistant hypervirulent <i>Klebsiella pneumoniae</i> (CR-hvKP) infection is gradually increasing globally. Phage therapy is a viable application as an alternative to antibiotics. However, clinical application of phage therapy is restricted by phage resistance. To further explore the mechanism underlying phage resistance, particularly the difference observed between <i>in vivo</i> and <i>in vitro</i>, we employed a mouse intra-abdominal infection model to assess the antibacterial properties of two lytic phages and further isolate and characterize phage-resistant mutants. We identified that the majority of the mutation sites in the phage-resistant <i>K. pneumoniae</i> mutants were located in the capsular polysaccharide (CPS) gene cluster, as determined through genomic and transcriptomic analysis. However, some <i>K. pneumoniae</i> phage-resistant mutants, including RM01, RM02, and RM12, developed phage resistance by downregulating CPS and the respective transcriptional regulators without any mutations in the CPS gene. In summary, these findings provide further evidence supporting phage therapy, particularly addressing the issue of CR-hvKP infections.IMPORTANCEThe global rise in antibiotic resistance has rekindled interest in utilizing bacteriophage therapy as a potential solution. In this study, we explored the therapeutic potential of two novel bacteriophages, with a focus on their <i>in vivo</i> efficacy using mouse models, and analyzed the probable mechanisms of phage resistance in bacteria. Our results indicated that in a murine infection model, phages JLBP1001 and JLBP1002 for <i>Klebsiella pneumoniae</i> were highly effective, significantly improving mouse survival. We further characterized and analyzed phage-resistant <i>K. pneumoniae</i> isolated from the mice and found that the resistance mechanisms in an <i>in vivo</i> environment are primarily concentrated in the capsular polysaccharide gene cluster. In RM01, RM02, and RM12, <i>putA</i> contributes to phage resistance through point mutations. These insights are important for optimizing phage-based therapies, particularly in the context of multidrug-resistant bacterial infections.
BibTeX
@inproceedings{dou2026investigation,
  author = {Lei Dou and Jiayang Li and Wenqi Wu and Li Xu and Mingjie Qiu and Shuanghong Yang and Jiajie Wang and Sai Tian and Zhitao Zhou and Meilin Wu and Yun Zhao and Xiuwen Wu and Jianan Ren},
  title = {{Investigation of the therapeutic efficacy and resistance mechanisms of lytic phages targeting ST218 KL57 CR-hvKP}},
  booktitle = {mSystems},
  year = {2026},
  doi = {10.1128/msystems.01476-25},
}
Figure